APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
+0.00%Price chart
Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.8x
Market Cap
$10.22B
MomentumView details →
1D Return
+0.00%
YTD Return
+78.95%
RSI (14)
78.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.8x
Market Cap
$10.22B
RSI (14)
78.7
MomentumView details →
1D Return
+0.00%
YTD Return
+78.95%
SummaryUpdated Jun 1, 2026
Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company founded in 2022 and headquartered in Waltham, Massachusetts. The company went public in July 2023, raising capital to advance its pipeline of extended half-life monoclonal antibody therapies. Apogee focuses on developing innovative treatments for inflammatory and immunological conditions, particularly atopic dermatitis and chronic obstructive pulmonary disease, using proprietary antibody engineering technologies designed to improve patient convenience and treatment outcomes.
Similar companies
Latest newsMore news →
AbbVie completed its $11 billion acquisition of Apogee Therapeutics.1d agoDeutsche Bank AG acquired a new stake in Apogee Therapeutics Inc., purchasing 98,979 shares valued at approximately $13.1 million during the second quarter, as disclosed in a 13F filing.12d agoApogee Therapeutics insider Carl Dambkowski sold 5,500 shares of the company's stock on August 5, 2026, at an average price of $134.17, totaling $737,935.00.25d ago